Poly Lactic‐Co‐Glycolic Acid (PLGA) Copolymer and Its Pharmaceutical Application

Pandey, Abhijeet; Jain, Darshana

doi:10.1002/9781119041412.ch6

Cited by 35 publications

(28 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, meglumine antimoniate would appear a first-choice drug for sustained intralesional release in microsphere depot. However, because it is a highly hydrophilic drug, a complex double-wall process is necessary to counteract the strong initial burst, short release period, and low encapsulation efficiency that normally accompanies encapsulation of hydrophilic drugs in PLA/PLGA particles (32,33). Local injections with 130-nm liposomes loaded with meglumine antimoniate, miltefosine, and paromomycin have also been tested in L. major-infected mice, but only multiple doses of miltefosine-loaded formulations showed significant therapeutic effects (34).…”

Section: Discussionmentioning

confidence: 99%

Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis

Sousa-Batista

Pacienza-Lima

Arruda-Costa

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Conventional chemotherapy of cutaneous leishmaniasis (CL) is based on multiple parenteral or intralesional injections with systemically toxic drugs. Aiming at a single-dose localized therapy, biodegradable poly(lactic-co-glycolic acid) (PLGA) microparticles loaded with 7.8% of an antileishmanial nitrochalcone named CH8 (CH8/PLGA) were constructed to promote sustained subcutaneous release. , murine macrophages avidly phagocytosed CH8/PLGA smaller than 6 μm without triggering oxidative mechanisms. Upon 48 h of incubation, both CH8 and CH8/PLGA were 40 times more toxic to intracellular than to macrophages. , BALB/c were given one or three subcutaneous injections in the infected ear with 1.2 mg/kg of CH8 in free or CH8/PLGA forms, whereas controls received three CH8-equivalent doses of naked PLGA microparticles or meglumine antimoniate (Glucantime; Sanofi-Aventis). Although a single injection with CH8/PLGA reduced the parasite loads by 91%, triple injections with free CH8 or CH8/PLGA caused 80 and 97% reductions, respectively, in relation to saline controls. Meglumine antimoniate treatment was the least effective (only 36% reduction) and the most toxic, as indicated by elevated alanine aminotransferase serum levels. Together, these findings show that CH8/PLGA microparticles can be effectively and safely used for single-dose treatment of CL.

show abstract

Section: Discussionmentioning

confidence: 99%

Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis

Sousa-Batista

Pacienza-Lima

Arruda-Costa

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…It can be easily hydrolysed by body fluids into non-toxic metabolites monomers, lactic acid, and glycolic acid causing minimal systemic toxicity (Arpagaus, 2019b;Bartolucci, 2017;Danhier et al, 2012;Essa et al, 2020;Pandey & Jain, 2015;Swider et al, 2018). It is available for commercial use and licensed by the United States Food and Drug Administration (US FDA) and the European Medicine Agency (EMA) at different molecular weights and lactide/glycolide ratios (Bartolucci, 2017;Danhier et al, 2012;Hirenkumar & Steven, 2012;Pandey & Jain, 2015). Interestingly, PLGA copolymer can be stored in powder form for a lengthy period (Swider et al, 2018).…”

Section: Proposed Strategiesmentioning

confidence: 99%

“…Several formulation parameters need to be considered to prepare an ideal PLGA-based nanoparticle. The PLGA molecular weight and the ratio of poly-lactic acid to polyglycolic acid can be manipulated to obtain the desired degradation rate and mechanical strength (Arpagaus, 2019b;Danhier et al, 2012;Pandey & Jain, 2015). The higher molecular weight of PLGA possesses more structural stability, therefore it degrades slowly in in-vivo (Arpagaus, 2019b;Essa et al, 2020).…”

Section: Proposed Strategiesmentioning

confidence: 99%

Potential Nanospray Inhalation of Remdesivir and Hydroxychloroquine using Poly (lactic-co-glycolic) Acid as Fast Delivery for Covid-19 Treatment.

Taher

Shaari

Susanti

2021

JoP

View full text Add to dashboard Cite

Introduction: The oral medication of remdesivir and hydroxychloroquine face several limitations in covid-19 therapy. Despite having the first-pass metabolism, it also has a limitation in the patient who has hospitalised with a severe covid-19 infection. It is especially for a drug that is targeting the angiotensin-converting enzyme II (ACE2) receptor where the receptors are found abundantly in the lung, kidney, heart, and gastrointestinal tract. Therefore, an alternative delivery such as nanospray inhalation would provide a great benefit to those patients. Methods: Scientific sources from Scopus, PubMed, Google Scholar, EBSCO, ScienceDirect, and Elsevier were accessed for publication of this review article regarding the nanospray inhalation for Covid-19. Results: Since the main organ infected by SARS-CoV-2 is the esophagus and lung, inhalation may be the best route to deliver the drug to the site of action. It is proposed that poly (lactic-co-glycolic) acid to be used in the formulation. Conclusion: Poly (lactic-co-glycolic) acid (PLGA) is considered a suitable polymer since it is biocompatible and noncytotoxic, it is the most widely applied in drug delivery either as carrier or excipient for the optimal formulation and distribution of the drugs. Dry powder inhalation of remdesivir and hydroxychloroquine may be an alternative way to deliver the drug against Covid-19.

show abstract

“…One extensively investigated polymer is poly (lactic-co-glycolic acid) (PLGA), synthetic thermoplastic aliphatic biocompatible polyester. There are specific formulations based on PLGA and its related homopolymers; poly (lactic acid) (PLA) and poly (glycolic acid) (PGA), which have been approved by the US Food and Drug Administration (FDA) for medical applications ( Pandey et al, 2015 ). PLGA NPs have also proved their potential as drug delivery systems for many therapeutic agents (e.g., chemotherapy, antibiotics, antiseptic, anti-inflammatory and antioxidant drugs, proteins), and can be favorable for tumor- and/or DNA-targeting ( Danhier et al, 2012 ; Berthet et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

PLGA-Based Nanoparticles in Cancer Treatment

et al. 2018

View full text Add to dashboard Cite

Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug delivery, hyperthermia, and photodynamic therapy. Poly (lactic-co-glycolic acid) (PLGA)-based materials are frequently used in such setups. This review article gives an overview of the properties of previously reported PLGA nanoparticles (NPs), their behavior in biological systems, and their use for cancer therapy. Strategies are emphasized to target PLGA NPs to the tumor site passively and actively. Furthermore, combination therapies are introduced that enhance the accumulation of NPs and, thereby, their therapeutic efficacy. In this context, the huge number of reports on PLGA NPs used as drug delivery systems in cancer treatment highlight the potential of PLGA NPs as drug carriers for cancer therapeutics and encourage further translational research.

show abstract

Poly Lactic‐Co‐Glycolic Acid (PLGA) Copolymer and Its Pharmaceutical Application

Cited by 35 publications

References 112 publications

Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis

Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis

Potential Nanospray Inhalation of Remdesivir and Hydroxychloroquine using Poly (lactic-co-glycolic) Acid as Fast Delivery for Covid-19 Treatment.

PLGA-Based Nanoparticles in Cancer Treatment

Contact Info

Product

Resources

About